Stock HYPR HYPERFINE, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Hyperfine, Inc.

Equities

HYPR

US44916K1060

Delayed Nasdaq
Other stock markets
 02:27:55 2024-05-17 pm EDT 		5-day change 1st Jan Change
0.89 USD +5.83% Intraday chart for Hyperfine, Inc. +12.66% -20.54%
May. 14 Jefferies Downgrades Hyperfine to Hold From Buy, Price Target is $0.90 MT
May. 13 Transcript : Hyperfine, Inc., Q1 2024 Earnings Call, May 13, 2024

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Jefferies Downgrades Hyperfine to Hold From Buy, Price Target is $0.90
MT
Transcript : Hyperfine, Inc., Q1 2024 Earnings Call, May 13, 2024
Hyperfine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Earnings Flash (HYPR) HYPERFINE Posts Q1 Revenue $3.3M, vs. Street Est of $3.1M
MT
Hyperfine, Inc. Reports First Quarter 2024 Financial Results
GL
Hyperfine, Inc. Provides Earnings Guidance for the Year 2024
CI
Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets
AQ
Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets
BU
Hyperfine, Inc. to Expand Global Market Reach in European Markets
CI
Hyperfine, Inc. to Announce First Quarter 2024 Financial Results on May 13, 2024
BU
Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop System Images across Multiple Care Settings and Clinical Conditions
AQ
Hyperfine, Inc. Takes the Stage at ISMRM with Seventeen Abstracts Assessing the Potential of Using Swoop® System Images Across Multiple Care Settings and Clinical Conditions
BU
Hyperfine, Inc. - Leading Institutions Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
AQ
Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
BU
Hyperfine, Inc. Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in Care PMR Study
CI
Wells Fargo Trims Hyperfine's Price Target to $1.60 From $2.10, Keeps Equalweight Rating
MT
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating
MT
Transcript : Hyperfine, Inc., Q4 2023 Earnings Call, Mar 21, 2024
Earnings Flash (HYPR) HYPERFINE Posts Q4 Revenue $2.7M
MT
Hyperfine, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HYPR Stock
  4. News Hyperfine, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW